Biotech Making Moves: Lexaria (LEXX) Completes Dosing in Second GLP-1 Human Pilot Study

Today biotech company and global innovator in drug delivery platforms Lexaria Bioscience Corp. (LEXX), announced its human pilot study #2, GLP-1-H24-2 has now completed all dosing.

This Study was a three-arm, crossover investigation comparing three 7 mg semaglutide dose formulations which were a positive control Rybelsus® swallowed tablet, DehydraTECH-semaglutide swallowed capsules, and for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet.

Due to the acidic environment of the stomach which, seriously breaks down swallowed GLP-1 drugs can lead to exceptionally low blood absorption rates of less than 1% in the absence of an absorption technology.  In an effort to enhance absorption, this study will be the first to investigate whether DehydraTECH-enhanced semaglutide can absorb at any level systemically through the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed administration, and with some effective drug delivery into the bloodstream.

All blood samples collected during the study are now being transported to the bioanalytical lab for analysis and study results are anticipated to be announced in late August or early September.

“Lexaria is delighted that our contracted clinical research organization was able to complete the active phase of the Study on schedule,” said Chris Bunka, Chief Executive Officer of the Company. “The results of this Study are expected to validate our earlier work with semaglutide, and also to discover whether it is possible to achieve any absorption of this market-leading GLP-1 drug through the tissues of the mouth.”

Additionally, Lexaria announced three new patent awards for antiviral drug delivery and for treating epilepsy. The company currently holds 46 granted patents worldwide.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Biotech Making Moves: Lexaria (LEXX) Completes Dosing in Second GLP-1 Human Pilot Study

Ashlee Vogenthaler

Markets Editor